Emerging Therapies Reshape the Open-Angle Glaucoma Treatment Market Outlook

PolyActiva's PA5108 Ocular Implant uses its proprietary Prezia Sustained Drug Delivery Technology to deliver latanoprost free acid at a controlled daily dose. The implant is designed to provide zero-order drug release and undergo rapid, complete, and non-toxic biodegradation after treatment completion. PA5108 is currently being evaluated in Phase II clinical trials for primary open-angle glaucoma.

In December 2024, PolyActiva reported positive Phase II findings for PA5108, with the study meeting its primary efficacy and safety endpoints and demonstrating meaningful IOP reductions over 26 weeks.

The anticipated introduction of these therapies could create new treatment paradigms, increase patient choice, and intensify competition across the open-angle glaucoma market.

To know more about new treatment for open-angle glaucoma, visit @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Recent Developments in Open-Angle Glaucoma

In June 2025, Qlaris Bio presented new data for its investigational lead candidate QLS-111 at the 2025 World Glaucoma Congress. The presentation included findings from the Phase II Osprey studies evaluating the compound in patients with primary open-angle glaucoma and ocular hypertension.

Understanding Open-Angle Glaucoma

Open-angle glaucoma is a chronic and progressive optic neuropathy characterized by an open anterior chamber angle, optic nerve damage, retinal nerve fiber layer thinning, and gradual peripheral vision loss. In advanced disease, central vision can also become affected, potentially resulting in blindness.

Elevated intraocular pressure is an important risk factor and remains the primary therapeutic target, although glaucoma can develop even when IOP is not substantially elevated. The condition commonly affects both eyes, although severity may differ between them. Many patients remain asymptomatic during the early stages, emphasizing the importance of regular screening and timely diagnosis.

Download the report to understand which factors are driving open-angle glaucoma epidemiology trends @ https://www.delveinsight.com/report-store/open-angle-glaucoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Open-Angle Glaucoma Epidemiology Outlook

DelveInsight's open-angle glaucoma market forecast incorporates patient-based epidemiological analysis across the United States, EU4, the UK, and Japan. The assessment examines historical and projected patient trends and evaluates factors influencing disease prevalence and diagnosis.